[HTML][HTML] Significance and in vivo detection of iron-laden microglia in white matter multiple sclerosis lesions

KM Gillen, M Mubarak, TD Nguyen, D Pitt - Frontiers in Immunology, 2018 - frontiersin.org
KM Gillen, M Mubarak, TD Nguyen, D Pitt
Frontiers in Immunology, 2018frontiersin.org
Microglia are resident immune cells that fulfill protective and homeostatic functions in the
central nervous system (CNS) but may also promote neurotoxicity in the aged brain and in
chronic disease. In multiple sclerosis (MS), an autoimmune demyelinating disease of the
CNS, microglia and macrophages contribute to the development of white matter lesions
through myelin phagocytosis, and possibly to disease progression through diffuse activation
throughout myelinated white matter. In this review, we discuss an additional compartment of …
Microglia are resident immune cells that fulfill protective and homeostatic functions in the central nervous system (CNS) but may also promote neurotoxicity in the aged brain and in chronic disease. In multiple sclerosis (MS), an autoimmune demyelinating disease of the CNS, microglia and macrophages contribute to the development of white matter lesions through myelin phagocytosis, and possibly to disease progression through diffuse activation throughout myelinated white matter. In this review, we discuss an additional compartment of myeloid cell activation in MS, i.e., the rim and normal adjacent white matter of chronic active lesions. In chronic active lesions, microglia and macrophages may contain high amounts of iron, express markers of proinflammatory polarization, are activated for an extended period of time (years), and drive chronic tissue damage. Iron-positive myeloid cells can be visualized and quantified with quantitative susceptibility mapping (QSM), a magnetic resonance imaging technique. Thus, QSM has potential as an in vivo biomarker for chronic inflammatory activity in established white matter MS lesions. Reducing chronic inflammation associated with iron accumulation using existing or novel MS therapies may impact disease severity and progression.
Frontiers